Immunoconjugates containing ricin A chain and either human anti-gp41 or CD4 kill H9 cells infected with different isolates of HIV, but do not inhibit normal T or B cell function

• Published in: Journal of acquired immune deficiency syndromes (1988) Vol. 3; no. 6; p. 609
• Main Authors: Till, M A, Ghetie, V, May, R D, Auerbach, P C, Zolla-Pazner, S, Gorny, M K, Gregory, T, Uhr, J W, Vitetta, E S
• Format: Journal Article
• Language: English
• Published: United States 1990
• Subjects: Antibodies, Monoclonal - pharmacology; B-Lymphocytes - drug effects; CD4 Antigens - pharmacology; Cell Line; HIV - drug effects; HIV Envelope Protein gp41 - immunology; Humans; Lymphocyte Culture Test, Mixed; Recombinant Proteins - pharmacology; Ricin - pharmacology; T-Lymphocytes - drug effects
• ISSN: 0894-9255

We have previously reported that immunoconjugates composed of deglycosylated ricin A chain coupled to either recombinant (r) CD4 or two different monoclonal human anti-gp41 antibodies (rCD4-dgA and anti-gp41-dgA, respectively) are specifically toxic to HIV-infected lines of human T cells (H9) and monocytes (U937). In order to further evaluate these immunoconjugates as potential therapeutic reagents for killing HIV-infected cells, H9 cells infected with five different isolates of HIV were used as target cells in vitro. All three HIV-specific immunoconjugates were toxic to H9 cells infected with each HIV isolate, but were virtually nontoxic to uninfected cells. Chloroquine markedly potentiated the specific toxicity of all three conjugates, particularly the anti-gp41-dgAs. None of the conjugates affected the ability of normal peripheral blood B cells to respond to mitogen or the ability of normal T cells to respond to alloantigens.